Viewing nowAyrika Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Intro Bio Pharma Co., Ltd.

MFDS item code 201907791 · Approved 2019.11.07 · Insurance code 052402250
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunct for treating partial seizures in patients with epilepsy, applicable whether secondary generalized symptoms are present or not. Additionally, it helps alleviate fibromyalgia symptoms. Patients are informed that this is an effective treatment option for various nerve-related diseases and pain management. This drug is used to improve symptoms of pain and seizures.
This medicine should be administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. Neuropathic pain — Peripheral neuropathic pain: Adults: The initial dose of this medicine may be 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. Neuropathic pain — Central neuropathic pain: Adults: The initial dose of this medicine may be 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy: Adults: The initial dose of this medicine may be 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. Fibromyalgia: The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily The total daily dose (mg/day) should be divided as specified in the dosing regimen. The supplemental dose is an additional dose administered as a single dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (aged 65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if depressive symptoms or mood changes occur during use, consult a healthcare professional immediately. Patients with hypersensitivity to any of the components should not take this medication. Diabetic patients may need to adjust their blood sugar control medications due to weight gain, so caution is advised. If symptoms of allergic reactions such as angioedema occur, stop taking the medication immediately and inform healthcare personnel. Elderly patients may experience dizziness, drowsiness, or loss of consciousness, thus they should exercise special caution, especially during the initial stages of use. If visual disturbances or changes in vision occur, discontinuing this medication may improve the symptoms. Before using this medication as monotherapy, consult with healthcare personnel about discontinuing any previously taken antiepileptic drugs. When stopping this medication, withdrawal symptoms such as insomnia, anxiety, and headaches may occur, so it should be tapered off gradually according to medical advice. Patients with a history of drug abuse may have a higher risk of misuse with this medication and should use it cautiously. Patients with reduced kidney function may require dosage adjustments. Patients with heart disease should be careful due to the risk of congestive heart failure. When taken with opioid analgesics, there is an increased risk of central nervous system depression. Patients with respiratory function impairment or the elderly should discuss the risk of severe respiratory depression with healthcare personnel. Women of childbearing age should use effective contraception prior to taking this medication in the early stages of pregnancy as it may pose a risk of fetal malformation. It is advisable to avoid activities that require alertness, such as driving or operating machinery, until dizziness or drowsiness has resolved. If severe skin reactions occur, stop taking the medication immediately and inform healthcare personnel. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, so immediate medical treatment is necessary. Keep out of reach of children, and do not transfer to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture ingress. It should be kept in a cool place between 15 degrees and 30 degrees.
A hard capsule with a reddish-brown upper part and a white lower part filled with a white or slightly yellow powder
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Intro Bio Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.